Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIT | P10721 | 10/20 | 0.74 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.69 |
| ▸ | NEK1 | Q96PY6 | 1/20 | 0.67 |
| ▸ | SGK1 | O00141 | 1/20 | 0.61 |
| ▸ | PLCG1 | P19174 | 1/20 | 0.60 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.57 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15833893 | 0.90 | KIT (0.86) | KITNTRK1NEK1PLCG1RIPK1 | |
| SCHEMBL8316940 | 0.85 | KIT (0.78) | KITNTRK1NEK1PLCG1RIPK1 | |
| SCHEMBL29337270 | 0.85 | SGK1 (0.83) | KITNTRK1SGK1RIPK1DYRK1A | |
| SCHEMBL17211637 | 0.84 | KIT (0.77) | KITNTRK1NEK1PLCG1RIPK1 | |
| SCHEMBL3763776 | 0.83 | SGK1 (0.69) | KITNTRK1SGK1DYRK1A | |
| SCHEMBL14319049 | 0.81 | DYRK1A (0.66) | KITNTRK1NEK1SGK1PLCG1 | |
| SCHEMBL3757332 | 0.81 | CAMKK2 (0.67) | KITNTRK1SGK1RIPK1DYRK1A | |
| SCHEMBL3697388 | 0.80 | PIK3CA (0.74) | KITNTRK1NEK1SGK1PLCG1 | |
| SCHEMBL14412694 | 0.80 | KIT (0.72) | KITNTRK1NEK1PLCG1RIPK1 | |
| SCHEMBL3759550 | 0.79 | SGK1 (0.71) | KITNTRK1NEK1SGK1PLCG1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120238588-A1 | 1H-Pyrrolo[2,3-B]Pyridines | GlaxoSmithKline, LLC | 2012-09-20 | — | — | US | claimed |
| US-20090233955-A1 | 1H-Pyrrolo[2,3-B]Pyridnes | GLAXOSMITHKLINE LLC | 2009-09-17 | — | — | US | claimed |
| EP-1828180-A1 | 1H-PYRROLO[2,3-BETA]PYRIDINES | SMITHKLINE BEECHAM CORPORATION (US) | 2007-09-05 | — | — | EP | claimed |
| WO-2006063167-A1 | 1H-PYRROLO[2,3-B]PYRIDINES | SMITHKLINE BEECHAM CORPORATION (US) | 2006-06-15 | — | — | WO | claimed |
| WO-2021006707-A1 | USE OF SGK1 INHIBITOR AS THERAPEUTIC AGENT FOR INFLAMMATORY NEUROLOGICAL DISEASES | 한양대학교 산학협력단 | 2021-01-14 | — | — | WO | disclosed |
| US-20120238588-A1 | 1H-Pyrrolo[2,3-B]Pyridines | GlaxoSmithKline, LLC | 2012-09-20 | — | — | US | disclosed |
| US-20090233955-A1 | 1H-Pyrrolo[2,3-B]Pyridnes | GLAXOSMITHKLINE LLC | 2009-09-17 | — | — | US | disclosed |
| EP-1828180-A1 | 1H-PYRROLO[2,3-BETA]PYRIDINES | SMITHKLINE BEECHAM CORPORATION (US) | 2007-09-05 | — | — | EP | disclosed |
| WO-2006063167-A1 | 1H-PYRROLO[2,3-B]PYRIDINES | SMITHKLINE BEECHAM CORPORATION (US) | 2006-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233955-A1 | 1H-Pyrrolo[2,3-B]Pyridnes | SGK1, SGK2, SGK3 | KIT 1364/4885NTRK1 964/4885NEK1 166/4885 |
| US-20120238588-A1 | 1H-Pyrrolo[2,3-B]Pyridines | SGK1, SGK2, SGK3 | KIT 1240/4885NTRK1 997/4885NEK1 165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.